A Study of ZW191 in Participants With Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Key facts

Study ID

NCT06555744

Run by

Zymeworks BC Inc.

People needed

145

Starts

2024-10-30

Expected to finish

2027-01-01

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
• Measurable disease per RECIST v1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
• Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
• Other adequate organ function.

You may not qualify if…

• Known additional malignancy that is progressing or requires active treatment or may interfere with study endpoints.
• Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of washout period.
• Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
• Severe chronic or active infections (including known active SARS-CoV-2 infection) requiring systemic therapy, including antibacterial, antifungal, or antiviral therapy.

Where it is running

• Yale University — New Haven, Connecticut, United States
• The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute — Columbus, Ohio, United States
• Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• NEXT Oncology — San Antonio, Texas, United States
• NEXT Virginia — Fairfax, Virginia, United States
• Linear Clinical Research — Nedlands, Australia
• Royal North Shore Hospital Northern Sydney Cancer Centre — St Leonards, Australia
• National Cancer Center Hospital East — Kashiwa-shi, Japan
• Saitama Medical University International Medical Center — Saitama, Japan
• National Cancer Center Hospital — Tokyo, Japan
• The Cancer Institute Hospital of JFCR — Tokyo, Japan
• National University Health System (NUHS) - National University Cancer Institute Singapore (NCIS) — Singapore, Singapore
• National Cancer Centre Singapore — Singapore, Singapore
• Curie Oncology — Singapore, Singapore
• National Cancer Center — Goyang-si, South Korea
• Seoul National University Bundang Hospital — Seongnam-si, South Korea
• Seoul National University Hospital — Seoul, South Korea
• Severance Hospital, Yonsei University Health System — Seoul, South Korea
• Asan Medical Center — Seoul, South Korea
• Samsung Medical Center — Seoul, South Korea
• Gangnam Severance Hospital — Seoul, South Korea
• Hospital Universitari Vall d'Hebron — Barcelona, Spain
• Hospital Universitario Reina Sofia — Córdoba, Spain
• Clínica Universidad de Navarra — Madrid, Spain
• NEXT Oncology Madrid — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.